Special Issue

AI-Driven Advanced Radiotherapy: Towards Personalized, Predictive and Adaptive Cancer Treatment

Message from the Guest Editors

The rapid advancement of artificial intelligence (AI) and machine learning (ML) has emerged as a transformative paradigm in healthcare and precision medicine by enabling computational models that represent key aspects of patient health. By incorporating data-driven AI and ML methods, these models can learn from multimodal patient data, enabling adaptive modeling, real-time monitoring, outcome prediction, and personalized clinical decision support. This Special Issue aims to highlight the rapidly evolving applications of AI-driven technologies in radiotherapy, showcasing how these innovations can revolutionize cancer care. We welcome original research articles, reviews, and clinical studies that present novel AI and ML applications in areas such as adaptive radiotherapy, personalized outcome prediction, radiobiological response modeling, and clinical decision support. We are particularly interested in contributions that demonstrate how AI approaches can enhance clinical workflows, treatment precision, and patient outcomes, ultimately improving quality of life.

Guest Editors

Dr. Zhen Tian

Department of Radiation and Cellular Oncology, The University of Chicago, Chicago, IL 60637, USA

Dr. Chaoqiong Ma

Department of Radiation Oncology, The University of Kansas Cancer Center, Kansas City, KS 66160, USA

Deadline for manuscript submissions

31 October 2026

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/si/260039

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/cancers

MDPI

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)